GLP-1 drugs linked to lower suicide risk in teens, but higher gynecologic tumor risk at high doses

Key Findings

⚠️ High-dose tirzepatide linked to gynecologic tumors

• Analysis of 91 randomized trials with 224,986 participants found that high-dose tirzepatide (15mg/week) was associated with a 137% increased risk of gynecologic tumors compared to placebo

• The absolute risk difference was 0.57%, meaning 1 in 176 patients would need to be treated to cause one additional gynecologic tumor

• Both high and low doses of tirzepatide showed 4-fold higher risk specifically for uterine tumors, while other GLP-1 drugs showed no significant tumor risk

🫀 Semaglutide cuts heart failure risk across all age groups

• In 1,145 patients with obesity-related heart failure, semaglutide improved symptoms and reduced body weight consistently whether patients were under 55 or over 75 years old

• Older adults (≥75 years) made up 25.5% of participants and showed similar benefits to younger patients in quality of life scores and 6-minute walk distance

• The drug's safety profile remained consistent across age groups, challenging concerns that older patients might not benefit or could experience more side effects

🤰 GLP-1 discontinuation before pregnancy leads to excess weight gain

• Women who used GLP-1 drugs before pregnancy but stopped gained 3.3 kg more during pregnancy than matched controls (13.7 kg vs 10.5 kg)

• These women had higher rates of preterm delivery (17% vs 13%), gestational diabetes (20% vs 15%), and pregnancy-related high blood pressure (46% vs 36%)

• The study included 448 exposed pregnancies, with 84% of women having obesity and 23% having pre-existing diabetes

🏥 Racial disparities in GLP-1 access among breast cancer survivors

• Among 119,430 breast cancer patients with diabetes, Asian patients were 36% less likely to receive GLP-1 drugs than white patients, while Black patients were 22% less likely

• These disparities persisted even among overweight and obese patients who would benefit most from the weight loss effects

• The gaps remained significant after accounting for other factors that might influence prescribing decisions

🧬 New azapeptide GLP-1 drug resists breakdown for over 24 hours

• Researchers created a modified GLP-1 drug that survived enzyme breakdown for more than 24 hours compared to standard versions that degrade quickly

• In obese mice, the new drug (AzaA8) reduced body weight and improved glucose handling without causing detectable inflammatory side effects

• The modification involves replacing specific carbon atoms with nitrogen atoms in the drug's backbone structure

🔬 Semaglutide reduces chronic cough risk compared to other diabetes drugs

• Among 427,555 adults with type 2 diabetes on GLP-1 drugs and 1.6 million on other diabetes medications, GLP-1 users had a 12% higher risk of developing chronic cough

• The increased risk was most pronounced compared to DPP-4 inhibitors (18% higher) and sulfonylureas (32% higher), but not SGLT2 inhibitors

• When patients with pre-existing acid reflux were excluded, the chronic cough risk increased to 29% higher for GLP-1 users